首页> 外文OA文献 >Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial

【2h】

Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial

机译：胰高血糖素的肽-1受体激动剂兴奋剂的安全性和疗效与日本2型糖尿病患者口腔抗糖尿病药物：随机，52周，开放标签，平行组试验的HOC分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Arihiro Kiyosue; Yutaka Seino; Keiji Nishijima; Heidrun Bosch-Traberg; Kohei Kaku;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial [J] . Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, Journal of diabetes investigation. . 2018,第4期

机译：胰高血糖素样肽-1受体激动剂利拉鲁肽与口服降糖药联合使用在日本2型糖尿病患者中的安全性和有效性：一项随机，52周，开放标签，平行组试验的事后分析
2. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study [J] . Harashima Shin-ichi, Inagaki Nobuya, Kondo Kazuoki, Diabetes, obesity & metabolism . 2018,第7期

机译：羊皮脂作为胰高血糖素肽-1受体激动剂作为2型糖尿病患者的胰高血糖素肽-1受体激动剂的疗效和安全性：A 52周，开放标签，第四阶段研究
3. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33) [J] . Hiroki Yokoyama, Koichi Hirao, Kohei Yamaguchi, Japanese Clinical Medicine . 2014,第5期

机译：利拉鲁肽与西格列汀在一项为期24周，多中心，开放标签，随机，平行组的日本2型糖尿病患者对磺脲类药物和/或一种或两种其他口服抗糖尿病药物反应不佳的研究中（JDDM 33）
4. Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized 52‐week open‐label parallel‐group trial [O] . Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, 2018

机译：胰高血糖素样肽-1受体激动剂利拉鲁肽与口服降糖药联合使用在日本2型糖尿病患者中的安全性和有效性：一项随机52周开放标签平行组试验的事后分析
5. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial [O] . Yutaka Seino, Mads Frederik Rasmussen, Tomoyuki Nishida, 2011

机译：胰高血糖素的肽-1类似物Liraglutide与磺酰脲类组合安全改善血糖测量对日本患者的血糖措施与2型糖尿病患者：结果为52周，随机，多中心试验

Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial

著录项

相似文献

相关主题

期刊订阅